Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cytotherapy. 2010 Sep;12(5):576-8. doi: 10.3109/14653249.2010.507330.

Defining the risks of mesenchymal stromal cell therapy.

Author information

  • 1Texas A&M Health Science College of Medicine, Institute for Regenerative Medicine at Scott & White, Temple, TX 76502, USA. Prockop@medicine.tamhsc.edu

Abstract

Abstract We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

PMID:
20735162
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk